Meda files US NDA for Dymista for SAR
This article was originally published in Scrip
Executive Summary
Sweden's Meda has filed an NDA for a nasal spray formulation of azelastine and fluticasone (Dymista; MP29-02) for the treatment of seasonal allergic rhinitis (SAR) in patients above the age of 12 with the US FDA.